PURPOSE: This study aims to investigate the feasibility of using simultaneous breast MRI and PET to assess the synergy of MR pharmacokinetic and fluorine-18 fluorodeoxyglucose (F-FDG) uptake data to characterize tumor aggressiveness in terms of metastatic burden and Ki67 status. METHODS: Twelve consecutive patients underwent breast and whole-body PET/MRI. During the MR scan, PET events were simultaneously accumulated. MR contrast kinetic model parametric maps were computed using the extended Tofts model, including the volume transfer constant between blood plasma and the interstitial space (K), the transfer constant from the interstitial space to the blood plasma (kep), and the plasmatic volume fraction (Vp). RESULTS: Patients with systemic metastases had a significantly lower kep compared to those with local disease (0.45 vs. 0.99 min, P = 0.011). Metastatic burden correlated positively with K and standardized uptake value (SUV), and negatively with kep. Ki67 positive tumors had a significantly greater K compared to Ki67 negative tumors (0.29 vs. 0.45 min, P = 0.03). A negative correlation was found between metabolic tumor volume and transfer constant (K or Kep). CONCLUSION: These preliminary results suggest that MR pharmacokinetic parameters and FDG-PET may aid in the assessment of tumor aggressiveness and metastatic potential. Future studies are warranted with a larger cohort to further assess the role of pharmacokinetic modeling in simultaneous PET/MRI imaging.
PURPOSE: This study aims to investigate the feasibility of using simultaneous breast MRI and PET to assess the synergy of MR pharmacokinetic and fluorine-18 fluorodeoxyglucose (F-FDG) uptake data to characterize tumor aggressiveness in terms of metastatic burden and Ki67 status. METHODS: Twelve consecutive patients underwent breast and whole-body PET/MRI. During the MR scan, PET events were simultaneously accumulated. MR contrast kinetic model parametric maps were computed using the extended Tofts model, including the volume transfer constant between blood plasma and the interstitial space (K), the transfer constant from the interstitial space to the blood plasma (kep), and the plasmatic volume fraction (Vp). RESULTS:Patients with systemic metastases had a significantly lower kep compared to those with local disease (0.45 vs. 0.99 min, P = 0.011). Metastatic burden correlated positively with K and standardized uptake value (SUV), and negatively with kep. Ki67 positive tumors had a significantly greater K compared to Ki67 negative tumors (0.29 vs. 0.45 min, P = 0.03). A negative correlation was found between metabolic tumor volume and transfer constant (K or Kep). CONCLUSION: These preliminary results suggest that MR pharmacokinetic parameters and FDG-PET may aid in the assessment of tumor aggressiveness and metastatic potential. Future studies are warranted with a larger cohort to further assess the role of pharmacokinetic modeling in simultaneous PET/MRI imaging.
Authors: Remy Lim; Anne Eaton; Nancy Y Lee; Jeremy Setton; Nisha Ohri; Shyam Rao; Richard Wong; Matthew Fury; Heiko Schöder Journal: J Nucl Med Date: 2012-08-14 Impact factor: 10.057
Authors: Einar K Rofstad; Siv H Tunheim; Berit Mathiesen; Bjørn A Graff; Ellen F Halsør; Kristin Nilsen; Kanthi Galappathi Journal: Cancer Res Date: 2002-02-01 Impact factor: 12.701
Authors: Wenche M Klerkx; Leon Bax; Wouter B Veldhuis; A Peter M Heintz; Willem PthM Mali; Petra H M Peeters; Karel G M Moons Journal: J Natl Cancer Inst Date: 2010-02-01 Impact factor: 13.506
Authors: Ji Youn Kim; Sung Hun Kim; Yun Ju Kim; Bong Joo Kang; Yeong Yi An; A Won Lee; Byung Joo Song; Yong Soo Park; Han Bi Lee Journal: Magn Reson Imaging Date: 2014-08-29 Impact factor: 2.546
Authors: Angela van Baardwijk; Christophe Dooms; Robert Jan van Suylen; Erik Verbeken; Monique Hochstenbag; Cary Dehing-Oberije; Dennis Rupa; Silvia Pastorekova; Sigrid Stroobants; Ulrich Buell; Philippe Lambin; Johan Vansteenkiste; Dirk De Ruysscher Journal: Eur J Cancer Date: 2007-05-23 Impact factor: 9.162
Authors: Akshat C Pujara; Roy A Raad; Fabio Ponzo; Carolyn Wassong; James S Babb; Linda Moy; Amy N Melsaether Journal: Breast J Date: 2016-02-04 Impact factor: 2.431
Authors: Amy M Fowler; Manoj Kumar; Leah Henze Bancroft; Kelley Salem; Jacob M Johnson; Jillian Karow; Scott B Perlman; Tyler J Bradshaw; Samuel A Hurley; Alan B McMillan; Roberta M Strigel Journal: Radiol Imaging Cancer Date: 2021-01-15
Authors: Jason Ostenson; Akshat C Pujara; Artem Mikheev; Linda Moy; Sungheon G Kim; Amy N Melsaether; Komal Jhaveri; Sylvia Adams; David Faul; Christopher Glielmi; Christian Geppert; Thorsten Feiweier; Kimberly Jackson; Gene Y Cho; Fernando E Boada; Eric E Sigmund Journal: Magn Reson Med Date: 2016-10-25 Impact factor: 4.668
Authors: Ramesh Paudyal; Yonggang Lu; Vaios Hatzoglou; Andre Moreira; Hilda E Stambuk; Jung Hun Oh; Kristen M Cunanan; David Aramburu Nunez; Yousef Mazaheri; Mithat Gonen; Alan Ho; James A Fagin; Richard J Wong; Ashok Shaha; R Michael Tuttle; Amita Shukla-Dave Journal: NMR Biomed Date: 2019-11-04 Impact factor: 4.044
Authors: Piotr Andrzejewski; Georg Wengert; Thomas H Helbich; Heinrich Magometschnigg; Dietmar Georg; Marcus Hacker; Pascal Baltzer; Paola Clauser; Panagiotis Kapetas; Petra Georg; Wolfgang Wadsak; Katja Pinker Journal: Contrast Media Mol Imaging Date: 2019-01-08 Impact factor: 3.161
Authors: Doris Leithner; Joao V Horvat; Blanca Bernard-Davila; Thomas H Helbich; R Elena Ochoa-Albiztegui; Danny F Martinez; Michelle Zhang; Sunitha B Thakur; Georg J Wengert; Anton Staudenherz; Maxine S Jochelson; Elizabeth A Morris; Pascal A T Baltzer; Paola Clauser; Panagiotis Kapetas; Katja Pinker Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-13 Impact factor: 9.236